Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

18 days and a few hours to wait after today.


Could it be one of these?

"Based on our in vivo studies, patients with skin-blistering diseases or ITP may be attractive candidates for the first in-human trial.Patients with chronic inflammatory demyelinating polyneuropathy may also be an interesting target population, because they respond to IVIg therapy with an up-regulation of the inhibitory Fc ? R (45), which was shown to be a critical IVIg-triggered effector pathway to dampen autoantibody activity in murine models (46, 47). Furthermore, given the documented effects of Fc sialylation in reducing IgG antibody-dependent cellular cytotoxicity activity, it may also be possible to use this enzymatic sialylation strategy to develop therapeutic antibodies with reduced effect or functions"

Can't wait to find out what it is going to be.

Once we know we can do more research on the potential.

Boing X 2